D. Western Therapeutics Institute, Inc. Stock price

Equities

4576

JP3548740004

Biotechnology & Medical Research

Market Closed - Japan Exchange 02:00:00 2024-03-28 am EDT 5-day change 1st Jan Change
128 JPY +2.40% Intraday chart for D. Western Therapeutics Institute, Inc. +4.07% -9.22%
Sales 2021 414M 2.73M Sales 2022 448M 2.96M Capitalization 8B 52.83M
Net income 2021 -148M -978K Net income 2022 -429M -2.83M EV / Sales 2021 11.5 x
Net cash position 2021 1.59B 10.53M Net cash position 2022 1.37B 9.03M EV / Sales 2022 14.8 x
P/E ratio 2021
-42.8 x
P/E ratio 2022
-18.1 x
Employees 20
Yield 2021 *
-
Yield 2022
-
Free-Float 78.18%
More Fundamentals * Assessed data
Dynamic Chart
D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024 CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2023 CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024 CI
D. Western Therapeutics Institute, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023 CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022 CI
D. Western Therapeutics Institute, Inc. announced that it has received ¥901.216203 million in funding from Whiz Partners Inc. CI
D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥901.216203 million in funding from Whiz Partners Inc. CI
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022 CI
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022 CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021 CI
D. Western Therapeutics Institute, Inc. Announces Consolidated Earnings Results for the Six Months Ended June 30, 2021 CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021 CI
UBiENCE Inc. announced that it expects to receive ¥100 million in funding from D. Western Therapeutics Institute, Inc. CI
D. Western Therapeutics Institute, Inc. Reports Consolidated Financial Results for the First Quarter Ended March 31, 2021 CI
More news
1 day+2.40%
1 week+4.07%
Current month+2.40%
1 month+0.79%
3 months-10.49%
6 months-30.81%
Current year-9.22%
More quotes
1 week
122.00
Extreme 122
128.00
1 month
120.00
Extreme 120
128.00
Current year
115.00
Extreme 115
152.00
1 year
115.00
Extreme 115
240.00
3 years
115.00
Extreme 115
357.00
5 years
115.00
Extreme 115
725.00
10 years
115.00
Extreme 115
3 550.00
More quotes
Managers TitleAgeSince
Founder 86 99-02-25
President 50 06-06-30
Chief Administrative Officer 59 14-02-28
Members of the board TitleAgeSince
Director/Board Member 61 10-02-28
President 50 06-06-30
Founder 86 99-02-25
More insiders
Date Price Change Volume
24-03-28 128 +2.40% 113 000
24-03-27 125 0.00% 35,200
24-03-26 125 0.00% 22,700
24-03-25 125 +0.81% 38,700
24-03-22 124 0.00% 22,200

Delayed Quote Japan Exchange, March 28, 2024 at 02:00 am EDT

More quotes
D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Company's drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock D. Western Therapeutics Institute, Inc. - Japan Exchange